Rudi Pauwels

Biography

 Rudi Pauwels founded Biocartis in 2007 and currently is a member of the Board of Directors where he acts as Chairman of the Strategy Committee. As a serial entrepreneur, he also co-founded several other European biotech companies, including Tibotec, Virco and Galapagos Genomics. Throughout his career, he has been driven by his relentless passion to find breakthrough medical solutions, focusing on unmet needs that improve the health outcome for the patient. Enabling worldwide access to personalized medicine for every patient, focused on a more tailored genetic profiling, has been a central theme - whether it is from a treatment or diagnostics point of view. Starting his career as a researcher at the internationally renowned Rega Institute for Medical Research in Leuven (Belgium), Mr. Pauwels has focused for more than two decades on the search and development of anti-HIV drugs and diagnostic tools that enable personalized HIV treatment, a number of which have been approved and introduced in the clinic while generating several billion USD revenue. With Biocartis, he is today revolutionizing molecular diagnostics with a new generation of high precision diagnostic solutions in oncology and infectious diseases, easily accessible on a global scale, and as such enable better and faster access to new, more personalized treatments for patients. Mr. Pauwels is (co)-author or more than 150 papers in peer-reviewed journals and is the recipient of several awards for his scientific and entrepreneurial accomplishments. Mr. Pauwels holds a PhD in Pharmaceutical Sciences from the Katholieke Universiteit Leuven, Belgium.

Research Interest

 Pharmaceutical Sciences